Fmoc-S-trityl-L-cysteine
Need Assistance?
  • US & Canada:
    +
  • UK: +

Fmoc-S-trityl-L-cysteine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fmoc-Amino Acids
Catalog number
BAT-003841
CAS number
103213-32-7
Molecular Formula
C37H31NO4S
Molecular Weight
585.70
Fmoc-S-trityl-L-cysteine
IUPAC Name
(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid
Synonyms
Fmoc-L-Cys(Trt)-OH; (R)-2-Fmoc-3-tritylsulfanyl-propionic acid; Fmoc-Cys(Trt)-OH; (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid; Fmoc-S-Trityl-L-Cysteine; N-Fmoc-S-trityl-L-cysteine; N-[(9H-Fluoren-9-ylMethoxy)carbonyl]-S-(triphenylMethyl)-L-cysteine
Appearance
White powder or off-white crystals
Purity
≥ 99.7% (HPLC, Chiral purity)
Density
1.270±0.06 g/cm3
Melting Point
168-182 °C
Boiling Point
763.4±60.0 °C
Storage
Store at 2-8 °C
InChI
InChI=1S/C37H31NO4S/c39-35(40)34(38-36(41)42-24-33-31-22-12-10-20-29(31)30-21-11-13-23-32(30)33)25-43-37(26-14-4-1-5-15-26,27-16-6-2-7-17-27)28-18-8-3-9-19-28/h1-23,33-34H,24-25H2,(H,38,41)(H,39,40)/t34-/m0/s1
InChI Key
KLBPUVPNPAJWHZ-UMSFTDKQSA-N
Canonical SMILES
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)SCC(C(=O)O)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46

Fmoc-S-trityl-L-cysteine, a protected amino acid essential in peptide synthesis, offers diverse applications in bioscience. Explore the intriguing world of Fmoc-S-trityl-L-cysteine with these notable applications:

Solid-Phase Peptide Synthesis (SPPS): Widely employed in SPPS, Fmoc-S-trityl-L-cysteine plays a pivotal role in introducing cysteine residues into peptides. The Fmoc group acts as a shield at the N-terminus, while the trityl group safeguards the sulfhydryl side chain. This dual protection scheme ensures seamless peptide elongation and precise cysteine integration, mitigating the risk of undesirable side reactions that could disrupt the synthesis process.

Disulfide Bridge Formation: The trityl-protected cysteine in Fmoc-S-trityl-L-cysteine offers a secure avenue for assembling peptide chains, followed by selective deprotection to facilitate disulfide bond creation. This step is crucial in crafting peptides and proteins that demand accurate disulfide bridge formation for optimal biological activity. The ability to fine-tune disulfide bond formation enhances peptide stability and functionality, paving the way for innovative bioengineering advancements.

Therapeutic Peptides: At the forefront of therapeutic peptide design and synthesis, Fmoc-S-trityl-L-cysteine plays a vital role in tailoring peptides with enhanced pharmacokinetic properties and heightened resistance to proteolytic degradation. By strategically incorporating cysteine residues at specific locations, researchers can develop modified peptides with promising applications in drug development across various medical conditions, offering a new frontier in personalized medicine.

Protein Engineering: In the realm of protein engineering, Fmoc-S-trityl-L-cysteine emerges as a key player in introducing site-specific mutations or modifications with precision. By integrating cysteine residues into proteins, scientists can facilitate targeted labeling, cross-linking, or conjugation reactions, enriching the toolbox for structural and functional analysis of proteins. These tailored modifications enable advanced investigations into protein function and interaction, opening avenues for cutting-edge research at the intersection of biology and technology.

1.Synthesis of the very acid-sensitive Fmoc-Cys(Mmt)-OH and its application in solid-phase peptide synthesis.
Barlos K1, Gatos D, Hatzi O, Koch N, Koutsogianni S. Int J Pept Protein Res. 1996 Mar;47(3):148-53.
S-4-methoxytrityl cysteine was synthesized and converted into the corresponding Fmoc-Cys(Mmt)-OH by its reaction with Fmoc-OSu. As compared to the corresponding Fmoc-Cys(Trt)-OH, the S-Mmt-function was found to be considerably more acid labile. Quantitative S-Mmt-removal occurs selectively in the presence of groups of the tert butyl type and S-Trt by treatment with 0.5-1.0% TFA. The new derivative was successfully utilized in the SPPS of Tyr1-somatostatin on 2-chlorotrityl resin. In this synthesis groups of the Trt-type were exclusively used for amino acid side-chain protection. Quantitative cleavage from the resin and complete deprotection was performed by treatment with 3% TFA in DCM-TES (95:5) for 30 min at RT. We observed no reduction of tryptophan under these conditions.
2.Acid-labile Cys-protecting groups for the Fmoc/tBu strategy: filling the gap.
Góngora-Benítez M1, Mendive-Tapia L, Ramos-Tomillero I, Breman AC, Tulla-Puche J, Albericio F. Org Lett. 2012 Nov 2;14(21):5472-5. doi: 10.1021/ol302550p. Epub 2012 Oct 17.
To address the existing gap in the current set of acid-labile Cys-protecting groups for the Fmoc/tBu strategy, diverse Fmoc-Cys(PG)-OH derivatives were prepared and incorporated into a model tripeptide to study their stability against TFA. S-Dpm proved to be compatible with the commonly used S-Trt group and was applied for the regioselecive construction of disulfide bonds.
3.A 'conovenomic' analysis of the milked venom from the mollusk-hunting cone snail Conus textile--the pharmacological importance of post-translational modifications.
Bergeron ZL1, Chun JB, Baker MR, Sandall DW, Peigneur S, Yu PY, Thapa P, Milisen JW, Tytgat J, Livett BG, Bingham JP. Peptides. 2013 Nov;49:145-58. doi: 10.1016/j.peptides.2013.09.004. Epub 2013 Sep 18.
Cone snail venoms provide a largely untapped source of novel peptide drug leads. To enhance the discovery phase, a detailed comparative proteomic analysis was undertaken on milked venom from the mollusk-hunting cone snail, Conus textile, from three different geographic locations (Hawai'i, American Samoa and Australia's Great Barrier Reef). A novel milked venom conopeptide rich in post-translational modifications was discovered, characterized and named α-conotoxin TxIC. We assign this conopeptide to the 4/7 α-conotoxin family based on the peptide's sequence homology and cDNA pre-propeptide alignment. Pharmacologically, α-conotoxin TxIC demonstrates minimal activity on human acetylcholine receptor models (100 μM, <5% inhibition), compared to its high paralytic potency in invertebrates, PD50 = 34.2 nMol kg(-1). The non-post-translationally modified form, [Pro](2,8)[Glu](16)α-conotoxin TxIC, demonstrates differential selectivity for the α3β2 isoform of the nicotinic acetylcholine receptor with maximal inhibition of 96% and an observed IC50 of 5.
4.Preparation of protected peptidyl thioester intermediates for native chemical ligation by Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) chemistry: considerations of side-chain and backbone anchoring strategies, and compatible protection for N-terminal cysteine.
Gross CM1, Lelièvre D, Woodward CK, Barany G. J Pept Res. 2005 Mar;65(3):395-410.
Native chemical ligation has proven to be a powerful method for the synthesis of small proteins and the semisynthesis of larger ones. The essential synthetic intermediates, which are C-terminal peptide thioesters, cannot survive the repetitive piperidine deprotection steps of N(alpha)-9-fluorenylmethoxycarbonyl (Fmoc) chemistry. Therefore, peptide scientists who prefer to not use N(alpha)-t-butyloxycarbonyl (Boc) chemistry need to adopt more esoteric strategies and tactics in order to integrate ligation approaches with Fmoc chemistry. In the present work, side-chain and backbone anchoring strategies have been used to prepare the required suitably (partially) protected and/or activated peptide intermediates spanning the length of bovine pancreatic trypsin inhibitor (BPTI). Three separate strategies for managing the critical N-terminal cysteine residue have been developed: (i) incorporation of N(alpha)-9-fluorenylmethoxycarbonyl-S-(N-methyl-N-phenylcarbamoyl)sulfenylcysteine [Fmoc-Cys(Snm)-OH], allowing creation of an otherwise fully protected resin-bound intermediate with N-terminal free Cys; (ii) incorporation of N(alpha)-9-fluorenylmethoxycarbonyl-S-triphenylmethylcysteine [Fmoc-Cys(Trt)-OH], generating a stable Fmoc-Cys(H)-peptide upon acidolytic cleavage; and (iii) incorporation of N(alpha)-t-butyloxycarbonyl-S-fluorenylmethylcysteine [Boc-Cys(Fm)-OH], generating a stable H-Cys(Fm)-peptide upon cleavage.
Online Inquiry
Verification code
Inquiry Basket